Novartis returned to invest in Caribou Biosciences, which is developing genome engineering technology for therapeutics, agriculture and industrial biotechnology.
US-based gene editing technology developer Caribou Biosciences closed a $30m series B round yesterday that included pharmaceutical firm Novartis.
The round also featured F-Prime Capital Partners, which is part of the Fidelity financial services group, Anterra Capital, Heritage Group, Maverick Capital Ventures, Mission Bay Capital, 5 Prime Ventures and Pontifax AgTech.
Founded by scientists from the University of California, Berkeley, Caribou is working on cellular analysis and engineering technology based on the Crispr gene editing system that will be used…
